CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial

By sjmartinez • December 18, 2024

Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809. Epub ahead of print. PMID: 39689718.

Tags: AML, CPX-351, Fellow, gemtuzumab ozogamicin, Hematology/Oncology, Publications

Susan Ettner, PhD and Dennis J. Slamon, MD, PhD Elected to the National Academy of Medicine

The UCLA Department of Medicine (DoM) is pleased to congratulate Susan Ettner, PhD and Dennis Slamon, MD, PhD, on their election to the National Academy[...]

B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman

Cai J, Sin D, Varda M, Lewis L, Yeh J. B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman. Clin Case Rep. 2026[...]

Putting the Patient at the Center of Patient-Centered Care

Rocque G, Nipp R, Sedrak MS. Putting the Patient at the Center of Patient-Centered Care. JCO Oncol Pract. 2026 Oct 16:OP2600798. doi: 10.1200/OP-26-00798. Epub ahead[...]